Adial Pharmaceuticals Overview
Get informed when a big investor buys or sells
+ Follow150.61%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, ADIL shows a ROE of 150.61%. That is above the Healthcare sector average of -75.84%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about -75.84%. Adial Pharmaceuticals is at 150.61%, which is higher that average. That is roughly 298.6% above the sector mean. Use the comparison chart on this page to see how ADIL stacks up against individual peers as well.
Check the historical chart to see whether ADIL's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Adial Pharmaceuticals with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Adial Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 150.61%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about -75.84%, while ADIL is at 150.61%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
